China Biotech Services Holdings Ltd (8037) Fair Value & Analysis
Healthcare · HK · Market cap HK$417M
Risks
Fair value as of: Aug 24, 2026
From 1 valuation models · updated today
Fair value updated Aug 24, 2026, revised from HK$0.0400 to HK$0.3100 (+675.0%) since Aug 13, 2026. Share price −4.6% over the past month.
Below-average quality, and screening another 50% overvalued on our models.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (HK$0.3900). The favourable scenario is already priced in.
- Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 24, 2026.
How to read this chart
60‑month range HK$0.2600 – HK$2.28 · fair‑value band HK$0.2400 – HK$0.3900 · the HK$0.6200 price screens above the HK$0.3100 fair value. Dashed = 300-day average. As of Aug 24, 2026.
Analysis
China Biotech Services Holdings Ltd (8037) currently trades at HK$0.6200, while our model-based Fair Value estimate is HK$0.3100, implying the stock looks roughly 50.0% overvalued today. The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, China Biotech Services Holdings Ltd generated revenue of HK$73.5M at a net margin of -93.6%. Revenue declined 9.0% year over year. It earns a return on equity of -40.6%. Net debt stands at HK$383M. Fundamentals as of Aug 24, 2026
Our scenario range runs from HK$0.2400 (bear case) to HK$0.3900 (bull case); at HK$0.6200, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 53% below its 52-week high and 107% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -54% fair-value upside, at -50%, 8037 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when 8037 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 24, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 31 · Market factors (momentum, volatility) 36
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
China Biotech Services Holdings Limited, an investment holding company, provides medical laboratory testing and health check services in the People's Republic of China and Hong Kong. The company operates through Medical and Health Related Services, Immunotherapy, Pharmaceutical Products, Insurance Brokerage, BNCT, and Others segments.
Full company description
China Biotech Services Holdings Limited, an investment holding company, provides medical laboratory testing and health check services in the People's Republic of China and Hong Kong. The company operates through Medical and Health Related Services, Immunotherapy, Pharmaceutical Products, Insurance Brokerage, BNCT, and Others segments. It also engages in the provision of tumor immune cell therapy and health management services; sale and distribution of health related and pharmaceutical products; insurance brokerage services; provision of boron neutron capture therapy treatment services, as well as provision of logistic services. The company was formerly known as Rui Kang Pharmaceutical Group Investments Limited and changed its name to China Biotech Services Holdings Limited in November 2017. China Biotech Services Holdings Limited was founded in 1996 and is headquartered in Causeway Bay, Hong Kong.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
China Biotech Services Holdings Ltd reported revenue of HK$73.5M in FY2025 versus HK$624M in FY2021, a compound −41.4%/yr. Reported net income was −HK$68.8M in FY2025.
8037 screens 50% overvalued. Compare with Thermo Fisher Scientific Inc →
Peer Group
Diagnostics & Research · 139 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Aug 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $603.01 | $308.19 | -49% |
| Danaher Corporation DHR | $205.79 | $103.88 | -50% |
| WuXi AppTec Co 2359 | HK$198.90 | HK$157.39 | -21% |
| Lonza Group LONN | CHF 566.20 | CHF 259.80 | -54% |
| IDEXX Laboratories, Inc IDXX | $570.58 | $255.77 | -55% |
| Agilent Technologies, Inc A | $148.24 | $61.53 | -58% |
| Waters Corporation WAT | $416.15 | $121.96 | -71% |
| IQVIA Holdings IQV | $236.66 | $132.17 | -44% |
| Illumina, Inc ILMN | $219.40 | $95.51 | -56% |
| Mettler-Toledo International Inc MTD | $1,419 | $615.78 | -57% |
Compare China Biotech Services Holdings Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is China Biotech Services Holdings Ltd (8037) overvalued or undervalued?
What is the fair value of 8037?
What is the quality score of 8037?
What is the revenue of China Biotech Services Holdings Ltd (8037)?
What is the net profit margin of 8037?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track China Biotech Services Holdings Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.